THRB and Hepatic steatosis: Although previous studies have already demonstrated the effectiveness of several THRβ agonists in reducing hepatic steatosis in animal models (47–49), the effect of THRβ-selective thyromimetics on the regression of preneoplastic lesions remained largely unexplored.